Market Place
Sourcing Support
Promontory Therapeutics Completes Enrollment of Phase 2 Trial of PT-112
08 Mar 2024 //
PR NEWSWIRE
Promontory Therapeutics to Present Data on PT-112 Mechanism of Action
26 Oct 2023 //
PR NEWSWIRE
Promontory Therapeutics Presents Data on the Molecular Effects of PT-112
14 Oct 2023 //
PR NEWSWIRE
Promontory Therapeutics Announces Early Phase 2 Clinical Trial Data From PT-112
05 Oct 2023 //
PR NEWSWIRE
Promontory Therapeutics to Present Molecular Effects of PT-112
04 Oct 2023 //
PR NEWSWIRE
Promontory Selected as the First International Biotech Company Member
29 Sep 2023 //
PR NEWSWIRE
Promontory Expands Phase 2 Trial of PT-112 in mCRPC to France
20 Jul 2023 //
PR NEWSWIRE
Promontory Announces Data from National Cancer Institute Phase 2 Trial of PT-112
02 Jun 2023 //
PR NEWSWIRE
Promontory Therapeutics to Participate in Business Development Strategies Panel
31 May 2023 //
PR NEWSWIRE
Promontory to Present Clinical Trial for PT-112 in Prostate Cancer at the ASCO
02 Feb 2023 //
PR NEWSWIRE
Promontory Therapeutics Presents Efficacy Data of PT-112 with PD-L1 Inhibition
08 Dec 2022 //
PRNEWSWIRE
Promontory Therapeutics Appoints Stan Musial as Chief Financial Officer
28 Nov 2022 //
PRNEWSWIRE
Promontory to Present Research on the Immunological Effects of PT-112
07 Nov 2022 //
PRNEWSWIRE
Promontory Reports PT-112`s Effects on Human Prostate Cancer Cell Mitochondria
26 Oct 2022 //
PRNEWSWIRE
Promontory Therapeutics Receives U.S. Patent for PT-112
20 Oct 2022 //
PRNEWSWIRE
Promontory Therapeutics to Present Research on PT-112 in Prostate Cancer
12 Oct 2022 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.